Wegovy vs Mounjaro Prices in the UK – Full Comparison

Both medications share common Wegovy vs Mounjaro side effects, including nausea, vomiting, diarrhoea, and constipation. However, intensity can differ. Mounjaro’s dual-action mechanism sometimes causes more pronounced gastrointestinal effects in early weeks, while Wegovy’s side effects tend to stabilise sooner. UK patients are strongly advised to consult their GP before starting either treatment, particularly those with pre-existing digestive or cardiovascular health conditions.

The Ozempic vs Mounjaro vs Wegovy cost comparison is a key factor for UK patients. Ozempic, used off-label for weight loss, costs around £150–£200 per month. Wegovy is priced at approximately £175–£250 monthly, while Mounjaro ranges from £150 to £270 depending on dosage. PPRX offers competitive pricing across all three, ensuring patients across the UK can access these treatments without unnecessary financial burden.

Clinical trials comparing Wegovy vs Mounjaro for weight loss show impressive outcomes for both. Wegovy users lost an average of 15% of body weight, while Mounjaro participants achieved up to 22% in the SURMOUNT trials. For UK adults managing obesity, Mounjaro appears to offer superior weight reduction overall. However, individual responses vary, and patient suitability must always guide prescribing decisions made by qualified healthcare professionals.

Many clinicians ask why is Mounjaro better than Wegovy. The answer lies in its dual-action formula. Mounjaro activates both GIP and GLP-1 receptors, while Wegovy targets only GLP-1. This dual mechanism enhances insulin sensitivity, reduces appetite more effectively, and boosts fat metabolism. For patients managing type 2 diabetes alongside obesity, Mounjaro’s broader mechanism of action makes it a clinically superior and increasingly preferred choice across UK practices.

Mounjaro vs Wegovy reviews from UK patients highlight key differences in experience. Mounjaro users frequently report faster appetite suppression and greater satisfaction, especially at higher doses. Wegovy reviewers praise its consistent results and manageable side effect profile. Both medications receive strong ratings on patient forums and health platforms. Ultimately, personal preference, medical history, and GP guidance shape which treatment suits each individual patient best.

The Mounjaro vs Wegovy dosage schedules are both structured around careful gradual titration. Wegovy progresses through five stages over 16 weeks, reaching a maintenance dose of 2.4 mg weekly. Mounjaro offers six titration steps, reaching up to 15 mg weekly. UK prescribers evaluate patient tolerance at each stage before advancing. PPRX supports patients throughout every dosage transition, offering expert guidance and competitive supply for the entire treatment journey.

For those asking Wegovy or Mounjaro which has less side effects, evidence suggests Wegovy may be slightly better tolerated in early stages, particularly for patients sensitive to nausea. Mounjaro’s more potent dual-action mechanism can cause stronger initial digestive discomfort. However, most side effects subside within weeks for both drugs. UK patients should discuss their tolerance and medical profile with a healthcare provider before deciding which medication best suits their lifestyle.